AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
28/06/2024 – AB Science today announces that the CHMP has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of ALS